US orphan drug status for Bayer's regorafenib
This article was originally published in Scrip
Executive Summary
The US FDA has granted orphan drug status to Bayer's investigational targeted anticancer regorafenib (BAY 73-4506) for the treatment of gastrointestinal stromal tumours (GIST).